Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl

PL EN


Preferences help
enabled [disable] Abstract
Number of results

Journal

2014 | 9 | 2 | 200-203

Article title

Intravascular large B-cell lymphoma with prominent cutaneous manifestation - case report

Content

Title variants

Languages of publication

EN

Abstracts

EN
Intravascular large B-cell lymphoma (IVLBCL) is a rare subtype of extranodal diffuse large B-cell lymphoma (DLBCL) characterized by selective growth of neoplastic cells within the vascular lumen. IVLBCL involves all types of organs and mostly is associated with poor prognosis, but patients with cutaneous variant have significantly better survival. In this article we report a case of 80-year-old woman with prominent cutaneous manifestation of intravascular large B-cell lymphoma.

Publisher

Journal

Year

Volume

9

Issue

2

Pages

200-203

Physical description

Dates

published
1 - 4 - 2014
online
13 - 2 - 2014

Contributors

author
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367, Wroclaw, Poland
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, 50-367, Wroclaw, Poland

References

  • [1] Pfleger L, Tappeiner J. On the recognition of systematized endotheliomatosis of the cutaneous blood vessels (reticuloendotheliosis?) Hautarzt 1959; 10: 359–363
  • [2] Pekic S, Milicevic S, Colovic N, Colovic M and Popovic V. Intravascular large B-cell lymphoma as a cause of hypopituitarism: gradual and late reversal of hypopituitarism after long-term remission of lymphoma with immunochemotherapy. Endocrine 2008; 34: 11–16 http://dx.doi.org/10.1007/s12020-008-9109-3[Crossref][WoS]
  • [3] Narimatsu H, Morishita Y and Saito S, Shimada K, Ozeki K, Kohno A, Kato Y, Nagasaka T. Usefulness of bone marrow aspiration for definite diagnosis of Asian variant of intravascular lymphoma: four autopsied cases. Leuk Lymphoma 2004; 45: 1611–1616 http://dx.doi.org/10.1080/10428190410001683769[Crossref]
  • [4] Ferreri AJ, Dognini GP and Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalban C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla Libera A Pertoldi B, Horvath B, szamor A, Zucca E, Cavalli F. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 2007; 92: 486–492 http://dx.doi.org/10.3324/haematol.10829[WoS][Crossref]
  • [5] Roglin J, Boer A. Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin. Br J Dermatol 2007; 157: 16–25 http://dx.doi.org/10.1111/j.1365-2133.2007.07954.x[Crossref][WoS]
  • [6] Martusewicz-Boros M, Wiatr E, Radzikowska E, Roszkowski-Sliz K and Langfort R. Pulmonary intravascular large B-cell lymphoma as a cause of severe hypoxemia. J Clin Oncol 2007; 25: 2137–2139 http://dx.doi.org/10.1200/JCO.2007.10.7201[Crossref][WoS]
  • [7] Fukushima A, Okada Y, Tanikawa T, Onaka T, Tanaka A, Higashi T, Tsukada J, Tanaka Y. Primary bilateral adrenal intravascular large B-cell lymphoma associated with adrenal failure. Intern Med 2003; 42: 609–614 http://dx.doi.org/10.2169/internalmedicine.42.609[Crossref][WoS]
  • [8] Katalinic D, Valkovic T, Lucin K, Rudez J. Intravascular lymphoma and thyroid gland Coll Antropol 2006; 30: 239–241
  • [9] Saleh Z, Kurban M, Ghosn S, Awar G, Kibbi AG. Generalized teleangiectasia: a manifestation of intravascular B-cell lymphoma. Dermatology 2008; 217: 318–320 http://dx.doi.org/10.1159/000151443[WoS][Crossref]
  • [10] Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A, Zucca E, Rossi G, Lopez-Guillermo A, Pavlovsky MA, Geerts ML, Candoni A, Lestani M, Asioli S, Milani M, Piris MA, Pileri S, Facchetti F, Cavalli F, Ponzoni M. Intravascula lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the “cutaneous variant”. Br J Haematol. 2004; 127: 173–183 http://dx.doi.org/10.1111/j.1365-2141.2004.05177.x[Crossref]
  • [11] Ponzoni M, Ferreri AJ, Campo E, Facchetti F, Mazzucchelli L, Yoshino T, Murase T, Pileri SA, Doglioni C, Zucca E, Cavalli F, Nakamura S. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. J Clin Oncol 2007; 25: 3168–3173 http://dx.doi.org/10.1200/JCO.2006.08.2313[WoS][Crossref]
  • [12] Colovic N, Jurisic V, Terzic T, Atkinson HD, Colovic M. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res. 2009; 301:689–92 http://dx.doi.org/10.1007/s00403-009-0967-1[Crossref][WoS]
  • [13] Shimada K, Matsue K, Yamamoto K, Murase T, Ichikawa N, Okamoto M, Niitsu N, Kosugi H, Tsukamoto N, Miwa H, Asaoku H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Ymaguchi M, Nakamura S, Naoe T, Kinoshita T. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. J Clin Oncol 2008; 26: 3189–3195 http://dx.doi.org/10.1200/JCO.2007.15.4278[Crossref]
  • [14] Ferreri AJ, Dognini GP, Bairey O, Szomor A, Montalban C, Horvath B, Demeter J, Uziel L, Soffietti R, Seymour JF, Ambrosetti A, Willemze R, Martelli M, Rossi G, Candoni A, De Renzo A, Doglioni C, Zucca E, Cavalli F, Ponzoni M. The addition of rituximab to anthracyclines-based chemotherapy significantly improves outcome in “Western” patients with intravascular large B-cell lymphoma. Br J Haematol 2008; 143: 253–257 http://dx.doi.org/10.1111/j.1365-2141.2008.07338.x[WoS][Crossref]
  • [15] Masaki Y, Dong L, Nakajima A, Iwao H, Miki M, Kurose N, Kinoshita E, Nojima T, Sawaki T, Kawanami T, Tanaka M, Shimoyama K, Kim C, Fukutoku M, Kawabata H, Fukushima T, Hirose Y, Takiguchi T, Konda S, Sugai S, Sugai S, Umehara H. Intravascular large B-cell lymphoma proposed of the strategy for early diagnosis and treatment of patients with rapid deteriorating condition. Int J Hematol 2009; 89: 600–610 http://dx.doi.org/10.1007/s12185-009-0304-7[Crossref]

Document Type

Publication order reference

Identifiers

YADDA identifier

bwmeta1.element.-psjd-doi-10_2478_s11536-013-0160-y
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.